K36 Therapeutics

About K36 Therapeutics

K36 Therapeutics is focused on creating breakthrough therapies for unmet medical needs of cancer patients worldwide, with a vision to translate epigenetic modulation of oncogenic pathways into first-in-class small molecule therapeutics.

Products & Services

KTX-1001:A first-in-class, oral, highly selective inhibitor of MMSET, targeting multiple myeloma patients with t(4;14) translocation. Currently in clinical trial (K36-MMSET-001) in the US, Canada, and Europe.

KTX-2001:An oral, selective NSD2 inhibitor for metastatic castration-resistant prostate cancer (mCRPC), studied as monotherapy and in combination with darolutamide. Trial (K36-STRIKE-001) to open in the US in 3Q25.

Specialties

Epigenetics Precision Medicine Oncology NSD2/MMSET Targeting Small Molecule Therapeutics

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series B T: - FT: Series B	A: 70000000 MR: - FA: 70 million FAN: 70000000	D: 2023-06-28 FD: 2023-06-28	6 investors

Series B Latest

2023-06-28

$70.0M

6 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

J

Jesus G. Berdeja

Director of Myeloma Research

S

Shaji Kumar

Professor of Medicine

T

Thomas Martin

Clinical Professor of Medicine

M

María-Victoria Mateos

M.D. Consultant Physician in the Haematology Department and Associate Professor of Medicine

N

Noopur Raje

Professor of Medicine, Director, Center for Multiple Myeloma

D

David Siegel

Chief of the Multiple Myeloma Division

View 25 more team members with Pro

Unlock Full Team Directory

Recent News